Cancer Immunotherapy for Hepatocellular Carcinoma: Current Drug Strategies, Resistance, Biomarkers, and Future Directions.

Zhong SS, Yu Y, Zhong XH, Xie J, Liu MS

Open source

DOI
10.2147/dddt.s653279
Published
2026
Container
Drug design, development and therapy
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.2147/dddt.s653279,
  title = {Cancer Immunotherapy for Hepatocellular Carcinoma: Current Drug Strategies, Resistance, Biomarkers, and Future Directions.},
  author = {Zhong SS and Yu Y and Zhong XH and Xie J and Liu MS},
  year = {2026},
  journal = {Drug design, development and therapy},
  doi = {10.2147/dddt.s653279},
  url = {https://doi.org/10.2147/dddt.s653279}
}

RIS

TY  - JOUR
TI  - Cancer Immunotherapy for Hepatocellular Carcinoma: Current Drug Strategies, Resistance, Biomarkers, and Future Directions.
AU  - Zhong SS
AU  - Yu Y
AU  - Zhong XH
AU  - Xie J
AU  - Liu MS
PY  - 2026
JO  - Drug design, development and therapy
DO  - 10.2147/dddt.s653279
UR  - https://doi.org/10.2147/dddt.s653279
ER  - 

APA

SS, Z., Y, Y., XH, Z., J, X., & MS, L. (2026). Cancer Immunotherapy for Hepatocellular Carcinoma: Current Drug Strategies, Resistance, Biomarkers, and Future Directions.. Drug design, development and therapy. https://doi.org/10.2147/dddt.s653279

Source records